en · de · es · fr · pt
selank-notes.peptides9002.com › Blog › Selank Background And Chemical Identity — Worked Examples

Selank Background And Chemical Identity — Worked Examples

By Editorial Desk · published 2025-07-28 · last reviewed 2025-09-10 · Blog

heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-09-10. Numbers and descriptions here follow the published literature rather than marketing material.

Selank Background And Chemical Identity

Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.

The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.

Origins and Proposed Mechanisms

Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.

Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.

Selank at a glance

PropertyValueNotes
Molecular classSynthetic heptapeptideStabilized analog of tuftsin
SequenceThr-Lys-Pro-Arg-Pro-Gly-ProSingle-letter form: TKPRPGP
Molecular formulaC33H57N11O9Monoisotopic mass about 751.9 Da
AppearanceWhite to off-white powderTypically supplied as lyophilized solid
SolubilityFreely soluble in waterAlso soluble in common polar solvents

Analytical Methods and Stability

Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.

Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.

Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.

Related pages on this site

Analytical Methods And Storage Stability

Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.

Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.

Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.

Storage, Analysis, and Regulatory Status

Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.

Identity and Structural Background

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.

Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.

Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.

Further detail

== External links == Peltola; et al. (2004). "News on cereulide, the emetic toxin of Bacillus Cereus". Appl Env Microbiol. 70 (8): 4996–5004.{{cite journal}}: CS1 maint: deprecated archival service (link) S. Pitchayawasin; M. Isobe; M. Kuse; T. Franz; N. Agata; M. Ohta (May 19, 2004). "Molecular diversity of cereulide" (PDF). International Journal of Mass Spectrometry. 235: 123–129. ISSN 1387-3806. Archived from the original (PDF) on March 13, 2005.

== Future work == In terms of future work, there is still a lot to be done in this field. Artificial cartilage is a new research topic and much is still unknown. There are a lot of unknown factors involving ASCPs and more studies need to be conducted to make a more supported conclusion about the regenerative functions of ASCPs. Additionally, growth factors have been thoroughly evaluated; however, specific combinations still need to be studied further in order to more effectively generate a tissue that can mimic the properties of natural cartilage. In 2021, Marc C. Hochberg, head of the division of rheumatology and clinical immunology at the University of Maryland School of Medicine, said that the "holy grail" would be a compound that reduced cartilage degradation and/or restored normal cartilage while reducing pain.

=== Keratin-like characteristics === Spongin also exhibits compositional similarities to keratin, particularly in its sulfur content and thermal stability. It withstands temperatures up to 300 °C, which is more characteristic for keratin than collagen. However, due to spongin's distinct biochemical features, its full molecular classification remains unknown.

=== RNA === In recent years, the biological function of triplex RNA has become more studied. Some roles include increasing stability, translation, influencing ligand binding, and catalysis. One example of ligand binding being influenced by a triple helix is in the SAM-II riboswitch where the triple helix creates a binding site that will uniquely accept S-adenosylmethionine (SAM). The ribonucleoprotein complex telomerase, responsible for replicating the tail-ends of DNA (telomeres) also contains triplex RNA believed to be necessary for proper telomerase functioning. The triple helix at the 3' end of the PAN and MALAT1 long-noncoding RNAs serves to stabilize the RNA by protecting the Poly(A) tail from deadenylation, which subsequently affect their functions in viral pathogenesis and multiple human cancers. Additionally, RNA triple helices can stabilize mRNAs by formation of a poly(A) tail 3'-end binding pocket.

Sources: en.wikipedia.org

Supporting material

=== Pre-discovery === In the late 1940s to early 1960s, the early days of making heavier and heavier transuranic elements, it was predicted that since such elements did not occur naturally, they would have shorter and shorter spontaneous fission half-lives, until they stopped existing altogether around element 108 (now called hassium). Initial work in synthesizing the heavier actinides seemed to confirm this. But the nuclear shell model, introduced in 1949 and extensively developed in the late 1960s by William Myers and Władysław Świątecki, stated that protons and neutrons form shells within a nucleus, analogous to electron shells. Noble gases are unreactive due to a full electron shell; similarly, it was theorized that elements with full nuclear shells – those having "magic" numbers of protons or neutrons – would be stabilized against decay. A doubly magic isotope, with magic numbers of both protons and neutrons, would be especially stabilized. Heiner Meldner calculated in 1965 that the next doubly magic isotope after 208Pb was 298Fl with 114 protons and 184 neutrons, which would be the centre of an "island of stability". This island of stability, supposedly from copernicium (Z = 112) to oganesson (Z = 118), would come after a long "sea of instability" from mendelevium (Z = 101) to roentgenium (Z = 111), and the flerovium isotopes in it were speculated in 1966 to have half-lives over 108 years. These early predictions fascinated researchers, and led to the first attempt to make flerovium, in 1968 with the reaction 248Cm(40Ar,xn).

== Side effects and precautions == Since alpha-glucosidase inhibitors prevent the degradation of complex carbohydrates into glucose, the carbohydrates will remain in the intestine. In the colon, bacteria will digest the complex carbohydrates, thereby causing gastrointestinal side effects such as flatulence and diarrhea. Since these effects are dose-related, it is generally advised to start with a low dose and gradually increase the dose to the desired amount. Pneumatosis intestinalis is another reported side effect. If a patient using an alpha-glucosidase inhibitor suffers from an episode of hypoglycemia, the patient should eat something containing monosaccharides such as glucose tablets or a soft drink containing HFCS. Since the drug will prevent the digestion of polysaccharides (or non-monosaccharides), non-monosaccharide foods may not effectively reverse a hypoglycemic episode in a patient taking an alpha-glucosidase inhibitor.

=== Cultural === The Houthis have also held a number of mass gatherings since the revolution. On 24 January 2013, thousands gathered in Dahiyan, Sa'dah and Heziez, just outside Sanaa, to celebrate Mawlid al-Nabi, the birth of Mohammed. A similar event took place on 13 January 2014 at the main sports' stadium in Sanaa. On this occasion, men and women were completely segregated: men filled the open-air stadium and football field in the centre, guided by appointed Houthi safety officials wearing bright vests and matching hats; women poured into the adjacent indoor stadium, led inside by security women distinguishable only by their purple sashes and matching hats. The indoor stadium held at least five thousand women—ten times as many attendees as the 2013 gathering.

Sources: en.wikipedia.org

Supporting material

Some symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgement, drowsiness, shallow breathing, staggering, and, in severe cases, coma or death. The lethal dosage of barbiturates varies greatly with tolerance and from one individual to another. The lethal dose is highly variable among different members of the class, with superpotent barbiturates such as pentobarbital being potentially fatal in considerably lower doses than the low-potency barbiturates such as butalbital. Even in inpatient settings, the development of tolerance is still a problem, as dangerous and unpleasant withdrawal symptoms can result when the drug is stopped after dependence has developed. Tolerance to the anxiolytic and sedative effects of barbiturates tends to develop faster than tolerance to their effects on smooth muscle, respiration, and heart rate, making them generally unsuitable for a long time psychiatric use. Tolerance to the anticonvulsant effects tends to correlate more with tolerance to physiological effects, however, meaning that they are still a viable option for long-term epilepsy treatment. Barbiturates in overdose with other CNS (central nervous system) depressants (e.g. alcohol, opiates, benzodiazepines) are even more dangerous owing to additive CNS and respiratory depressant effects. In the case of benzodiazepines, not only do they have additive effects, barbiturates also increase the binding affinity of the benzodiazepine binding site, leading to exaggerated benzodiazepine effects. (ex.

Ending months of speculation, on April 25, 2023, Biden confirmed he would run for reelection as president in the 2024 election, with Harris again as his running mate. On the day of his announcement, a Gallup poll found that Biden's approval rating was 37 percent, with most of those surveyed saying the economy was their biggest concern. During his campaign, Biden promoted higher economic growth and recovery. He frequently stated his intention to "finish the job" as a political rallying cry. U.S. Representative Dean Phillips ran against Biden in the 2024 Democratic presidential primaries. Phillips campaigned as a younger alternative to Biden, arguing that he would be a stronger opponent to Trump in the general election. Biden was not on the ballot in the January 23, New Hampshire primary, but won it in a write-in campaign with 63.8% of the vote. He had wanted South Carolina to be the first primary, and won that state on February 3 with 96.2% of the vote. Biden received 89.3% of the vote in Nevada and 81.1% of the vote in Michigan. On March 5 ("Super Tuesday"), he won 15 of 16 primaries, netting 80% or more of the vote in 13. Biden lost the American Samoa contest to venture capitalist Jason Palmer, becoming the first incumbent president to lose a contest while appearing on the ballot since Jimmy Carter in 1980. On March 6, Phillips suspended his campaign and endorsed Biden. On March 12, Biden reached more than the 1,968 delegates needed to win the Democratic nomination, becoming the presumptive nominee.

High-potency antipsychotics such as haloperidol, in general, have doses of a few milligrams and cause less sleepiness and calming effects than low-potency antipsychotics such as chlorpromazine and thioridazine, which have dosages of several hundred milligrams. The latter have a greater degree of anticholinergic and antihistaminergic activity, which can counteract dopamine-related side-effects. Atypical antipsychotic drugs have a similar blocking effect on D2 receptors; however, most also act on serotonin receptors, especially 5-HT2A and 5-HT2C receptors. Both clozapine and quetiapine appear to bind just long enough to elicit antipsychotic effects but not long enough to induce extrapyramidal side effects and prolactin hypersecretion. 5-HT2A antagonism increases dopaminergic activity in the nigrostriatal pathway, leading to a lowered extrapyramidal side effect liability among the atypical antipsychotics. Xanomeline/trospium chloride was approved for medical use in the United States in September 2024. It was the first antipsychotic to not act on D2 receptors. The mechanism of action instead relies on xanomeline's functional selectivity for the M1 and M4 muscarinic receptors, with trospium chloride, a peripherally selective antimuscarinic added to counteract xanomeline's unwanted peripheral muscarinic effects.

Sources: en.wikipedia.org

Frequently asked questions

What is Selank?

Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.

Where was Selank developed?

It was developed in Russia, at the Institute of Molecular Genetics of the Russian Academy of Sciences, during the 1990s. Most published research originates from Russian institutions. Independent international replication remains limited.

How does Selank differ from tuftsin?

Tuftsin is a natural tetrapeptide with the sequence Thr-Lys-Pro-Arg that participates in immune signaling. Selank extends that sequence with Pro-Gly-Pro at the C-terminus. The added residues are linked to greater resistance to enzymatic breakdown.

What is Selank made of?

It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.

Network